TGA also issues separate warning around Mounjaro and potential reduced effectiveness of contraception
The medicines regulator has added two new safety warnings around mental health and contraception for people taking high profile diabetes and weight loss drugs.
The Therapeutic Goods Administration (TGA) says because suicidal behaviour and ideation have been reported with these relatively new GLP-1 receptor agonists, doctors should “monitor patients for the emergence or worsening of depression, suicidal thoughts or behaviours, and/or any unusual changes in mood or behaviour”.
Continue reading…
Source: www.theguardian.com
Read full article
Post comments (0)